§ Same category · GLP-1 / metabolic peptides
AOD-9604 vs Orforglipron
Side-by-side price comparison across every tracked vendor. Updated every 4–6 hours.
Pepticker may earn affiliate commissions (typically 5-20%) from linked vendors. See our Affiliate Disclosure.
AOD-9604
12
vendors tracked
from $5.85/mg
Orforglipron
0
vendors tracked
AOD-9604
Lipolytic GH fragment
Operational
$29.24
$5.85/mg
In stockOn sale
B
Operational$39.99
$8.00/mg
In stock▲ 36.8% vs best
Operational
$41.00
$8.20/mg
In stock▲ 40.2% vs best
B-
Operational$49.00
$9.80/mg
In stock▲ 67.6% vs best
B
Operational$53.00
$10.60/mg
In stock▲ 81.3% vs best
Operational
$55.00
$11.00/mg
In stockOn sale▲ 88.1% vs best
B-
Watch$58.00
$11.60/mg
In stock▲ 98.4% vs best
Watch
$58.49
$11.70/mg
In stock▲ 100.0% vs best
Watch
$59.99
$12.00/mg
In stock▲ 105.2% vs best
B-
Watch$59.99
$12.00/mg
In stock▲ 105.2% vs best
| Vendor | Grade | Risk | Price | $/mg | Trend | Stock | |
|---|---|---|---|---|---|---|---|
| One Day Compounds US | B- | Operational | $29.24 On sale | $5.85 | In stock | Buy with code → | |
| Welli Labs US | B | Operational | $39.99 ▲ 36.8% | $8.00 | In stock | Visit → | |
| Core Peptides US | A | Operational | $41.00 ▲ 40.2% | $8.20 | In stock | Visit → | |
| Purus Peptides US | B- | Operational | $49.00 ▲ 67.6% | $9.80 | In stock | Visit → | |
| EZ Peptides US | B | Operational | $53.00 ▲ 81.3% | $10.60 | In stock | Visit → | |
| Ascension Peptides US | B | Operational | $55.00 On sale ▲ 88.1% | $11.00 | In stock | Visit → | |
| Ameano Peptides US | B- | Watch | $58.00 ▲ 98.4% | $11.60 | In stock | Visit → | |
| Australian Peptide Store AU | B- | Watch | $58.49 ▲ 100.0% | $11.70 | In stock | Visit → | |
| Felix Chemical Supply US | B- | Watch | $59.99 ▲ 105.2% | $12.00 | In stock | Visit → | |
| Modified Aminos US | B- | Watch | $59.99 ▲ 105.2% | $12.00 | In stock | Visit → |
Sort:
Last crawl 2026-11-12Sort:
2026-11-12Orforglipron
Oral small-molecule GLP-1 agonist
No current listings at 0.024mg.
About AOD-9604
A modified fragment of the C-terminus of human growth hormone studied for its lipolytic effects. Originally developed as an obesity drug candidate.
About Orforglipron
An oral non-peptide GLP-1 receptor agonist in Phase 3 for obesity and type-2 diabetes. Typically sold as capsules in research-compound form.